HomeREGULATORY
REGULATORY

CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
(Sep.7.2011)

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story

Commentary

Picture of Future Regulations on Investigator-Led Clinical Research Emerging

Lexicon

Drug requiring guidance:
要指導医薬品

The Column

Is Your Body Language Louder than Your Speech?

Archives

Shionogi Slapped with 1.3 Billion Yen in Back Taxes over ViiV Deal(Sep.17)
Novartis Files Jakavi for Polycythemia Vera in Japan(Sep.17)
Nippon Shinyaku to Gear Up R&D, Commercialization of Nucleic Acid Products(Sep.17)
MHLW Launches Discussions on Requirements for Legally Backed Clinical Research Core Hospitals(Sep.17)
Regulatory Reform Council to Monitor Progress on Proposed Pricing Overhaul of Innovative Drugs(Sep.17)

Most Read

1.
With Entry of S...
2.
Chuikyo’s Drug ...
3.
Chuikyo at Odds...
4.
LEO Pharma Laun...
5.
US FDA Approves...

News Calendar